Bio-Thera Solutions, Ltd. (SHSE: 688177)
Health Care · Biotechnology · CN
CN¥20.71
-5.35% today · -36.6% 1Y
Bio-Thera Solutions, Ltd. (SHSE: 688177) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.28B.
Over the last twelve months the share price has lost 36.6%, trading between 15.57 and 35.34.
Tweenvest scores Bio-Thera Solutions, Ltd. across four factors: quality 49/100, value 75/100, growth 100/100. Its strongest factor is growth.
688177 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.28B
- Revenue (TTM)
- $142.12M
- P/E
- —
- EPS
- -0.94
- Dividend yield
- —
- Beta (5Y)
- 0.37
- 52-week high
- CN¥35.34
- 52-week low
- CN¥15.57
- Avg volume (3M)
- —
- Shares outstanding
- 414.08M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.